EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs

Syed Arman Rabbani iD, Mohamed El-Tanani, Rakesh Kumar, Manita Saini, Yahia El-Tanani, Shrestha Sharma, Alaa A A Aljabali iD, Eman Hajeer iD, Manfredi Rizzo iD

Pharmaceuticals · 28.07.2025 · 18 (8) · 1130

DOI: 10.3390/ph18081130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.07.2025. Verfasst von Syed Arman Rabbani und 8 weiteren Autor:innen. Beteiligte Einrichtung: RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic Kidney Disease (CKD) is a major global health issue, with diabetes being its primary cause and cardiovascular disease contributing significantly to patient mortality. Recently, two classes of medications—sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—have shown promise in protecting both kidney and heart health beyond their effects on blood sugar control.

Methods

We conducted a narrative review summarizing the findings of different clinical trials and mechanistic studies evaluating the effect of SGLT2i and GLP-1 RAs on kidney function, cardiovascular outcomes, and overall disease progression in patients with CKD and DKD.

Results

SGLT2i significantly mitigate kidney injury by restoring tubuloglomerular feedback, reducing intraglomerular hypertension, and attenuating inflammation, fibrosis, and oxidative stress. GLP-1 RAs complement these effects by enhancing endothelial function, promoting weight and blood pressure control, and exerting direct anti-inflammatory and anti-fibrotic actions on renal tissues. Landmark trials—CREDENCE, DAPA-CKD, and EMPA-KIDNEY—demonstrate that SGLT2i reduce the risk of kidney failure and renal or cardiovascular death by 25–40% in both diabetic and non-diabetic CKD populations. Likewise, trials such as LEADER, SUSTAIN, and AWARD-7 confirm that GLP-1 RAs slow renal function decline and improve cardiovascular outcomes. Early evidence suggests that using both drugs together may offer even greater benefits through multiple mechanisms.

Conclusions

SGLT2i and GLP-1 RAs have redefined the therapeutic landscape of CKD by offering organ-protective benefits that extend beyond glycemic control. Whether used individually or in combination, these agents represent a paradigm shift toward integrated cardiorenal-metabolic care. A deeper understanding of their mechanisms and clinical utility in both diabetic and non-diabetic populations can inform evidence-based strategies to slow disease progression, reduce cardiovascular risk, and improve long-term patient outcomes in CKD.

Schlagwörter

Stichwörter der Autor:innen

(CKD) Chronic Kidney Disease(DKD) Diabetic Kidney DiseaseGLP-1 RAsSGLT2i

Autor:innen und Institutionen

  • RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
  • Amity Institute of Pharmacy, Amity University, Gurgaon 122413, Haryana, India.
  • Department of Pharmacy, Jagannath University, Bahadurgarh 124507, Haryana, India.
  • Geeta Institute of Pharmacy, Geeta University, Panipat 132145, Haryana, India.
  • Royal Cornwall Hospital, NHS Trust, Truro TR1 3LJ, UK.
  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.

ORCID-Profile: Syed Arman Rabbani, Alaa A A Aljabali, Eman Hajeer, Manfredi Rizzo

Zitieren

APA

Rabbani, S. A., El-Tanani, M., Kumar, R., Saini, M., El-Tanani, Y., Sharma, S., Aljabali, A. A. A., Hajeer, E., & Rizzo, M. (2025). Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals, 18(8), 1130. https://doi.org/10.3390/ph18081130

Vancouver

Rabbani SA, El-Tanani M, Kumar R, Saini M, El-Tanani Y, Sharma S, et al. Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs. Pharmaceuticals. 2025;18(8):1130. doi:10.3390/ph18081130

BibTeX
@article{Rabbani2025,
  author = {Rabbani, Syed Arman and El-Tanani, Mohamed and Kumar, Rakesh and Saini, Manita and El-Tanani, Yahia and Sharma, Shrestha and Aljabali, Alaa A A and Hajeer, Eman and Rizzo, Manfredi},
  title = {Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1130},
  doi = {10.3390/ph18081130}
}
Kostenlos starten →